Legal Opinion
Ferring B v. v. Watson Laboratories, Inc.
Court of Appeals for the Federal Circuit
Decided August 22, 2014No. 2014-1416PublishedCited by 40 opinions
1Opinion of the Court
Watson Laboratories, Inc.—Florida (“Watson”) appeals from the decisions of the United States District Court for the District of Nevada (i) holding that the subject matter of the asserted claims of Ferring B.V.’s (“Ferring”) U.S. Patents 7,947,739 (the “'739 patent”), 8,022,106 (the “'106 patent”), and 8,273,795 (the “'795 patent”) would not have been obvious under 35 U.S.C. § 103, (ii) finding that Watson’s generic tranexamic acid product infringed those claims under 35 U.S.C. § 271, consequently (iii) ordering the U.S. Food and Drug Administration (“FDA”) to reset the approval date of…
2Cases cited18 opinions
- United States v. United States Gypsum Co.Supreme Court of the United States · 1948
- Graham v. John Deere Co. of Kansas CitySupreme Court of the United States · 1966
- KSR International Co. v. Teleflex Inc.Supreme Court of the United States · 2007
- Microsoft Corp. v. i4i Ltd. PartnershipSupreme Court of the United States · 2011
- Amgen Inc., Plaintiff-Cross v. Hoechst Marion Roussel, Inc. (Now Known as Aventis Pharmaceuticals, Inc.) and Transkaryotic Therapies, Inc.Court of Appeals for the Federal Circuit · 2003
13 more not listed; retrieve them via the Exa API.
3Cited by40 opinions
- Vanda Pharmaceuticals Inc. v. West-Ward PharmaceuticalsCourt of Appeals for the Federal Circuit · 2018
- Cadence Pharmaceuticals Inc. v. Exela Pharma Sciences LLCCourt of Appeals for the Federal Circuit · 2015
- Insite Vision Incorporated v. Sandoz, Inc.Court of Appeals for the Federal Circuit · 2015
- Indivior Inc. v. Dr. Reddy's Laboratories, S.A.Court of Appeals for the Federal Circuit · 2019
- Sanofi-Aventis U.S., LLC v. Fresenius Kabi USA, LLCCourt of Appeals for the Federal Circuit · 2019
35 more not listed; retrieve them via the Exa API.